Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Totus Medicines
BeOne Medicines
BeOne Medicines
Context Therapeutics Inc.
"Oncostar" LLC
Bayer
NiKang Therapeutics, Inc.
Aktis Oncology, Inc.
Novartis
EMD Serono
Regor Pharmaceuticals Inc.
Seagen Inc.
Eli Lilly and Company
Compass Therapeutics
Pliant Therapeutics, Inc.
Eli Lilly and Company
Pfizer
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
AstraZeneca
BeOne Medicines
Exelixis
Incyte Corporation
Mersana Therapeutics
Cellectar Biosciences, Inc.
AbbVie
Eli Lilly and Company
Eli Lilly and Company
Iambic Therapeutics, Inc
Nammi Therapeutics Inc
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Stemline Therapeutics, Inc.
ExpreS2ion Biotechnologies
Radionetics Oncology
Boundless Bio, Inc.
Halda Therapeutics OpCo, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Novartis
Exscientia AI Limited
Fate Therapeutics
Conjupro Biotherapeutics, Inc.
Epsilogen Ltd
Conjupro Biotherapeutics, Inc.
Pfizer
Genentech, Inc.
Regor Pharmaceuticals Inc.